Sovaldi

PreclinicalSmall molecule

Sovaldi is one of 48 small molecule programs targeting Chronic Hepatitis C Virus Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis C Virus InfectionActive, not recruiting

Chronic Hepatitis C Virus InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Chronic Hepatitis C Virus Infection

#DrugCompanyPhaseTrials

Tecentriq

Roche

Approved

1 2

Avapro

Lescol

Actos

Calciferol

Alnylam Pharmaceuticals

Neoral

Incivek

Vertex Pharmaceuticals

Phase 3

4 8

Paxil

SSebela Pharmaceuticals Development LLC

Approved

—9

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

—10

Alinia

RRomark Laboratories L.C.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ALD3 trials

A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT02605798·24 enrolled

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT03062423·36 enrolled

A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT02953535·36 enrolled

Chronic Hepatitis C Virus Infection1 trial

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

Completed· Gilead logo

Gilead··NCT02783976·25 enrolled

CAR1 trial

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT02491450·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sovaldi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sovaldi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sovaldi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Gilead

Sovaldi

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ALD3 trials

Chronic Hepatitis C Virus Infection1 trial

CAR1 trial

References

Drug Info

Quick Facts

Related News